Psoralen(Synonyms: 补骨脂素; Ficusin)

发表于由

天然产物 天然产物苯丙素类 Phenylpropanoids

Psoralen (Synonyms: 补骨脂素; Ficusin) 纯度: 99.92%

Psoralen (Ficusin) 是从补骨脂种子中提取的一种香豆素。Psoralen 具有多种生物学特性，包括抗癌、抗氧化、抗抑郁、抗癌、抗菌、抗病毒等。

Psoralen(Synonyms: 补骨脂素; Ficusin)

Psoralen Chemical Structure

CAS No. : 66-97-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥605 In-stock
10 mg ￥550 In-stock
50 mg ￥1850 In-stock
100 mg ￥2950 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Psoralen 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Antiviral Compound Library
  • Lipid Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Food-Sourced Compound Library

生物活性

Psoralen (Ficusin) is a coumarin isolated from the seeds of Fructus Psoraleae. Psoralen exhibits a wide range of biological properties, including anti-cancer, antioxidant, antidepressant, anticancer, antibacterial, and antiviral, et al[1].

体外研究
(In Vitro)

Psoralen (10-500 μM; 24-48 hours) inhibits cell viability in a concentration- and time-dependent manner in L02 and HepG2 cells. In L02 cells, Psoralen at 400 μM does not significantly change extracellular LDH levels, and 400 μM or 450 μM psoralen inhibits 50–60% of cell viability[1].
Psoralen (150-450 μM; 24 hours) induces significant S-phase arrest in L02 cells in time- and dose-dependent manners, but it does not exhibits significant change in the cycle distribution of HepG2 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: L02 and HepG2 cells
Concentration: 10 μM, 50 μM,100 μM, 200 μM, 300 μM,400 μM,450 μM,500 μM
Incubation Time: 24 or 48 hours
Result: Inhibited the viability of L02 and HepG2 cells mainly by suppressing cell proliferation rather than causing cell death.

Cell Cycle Analysis[1]

Cell Line: L02 and HepG2 cells
Concentration: 150 μM; 300 μM; 450 μM
Incubation Time: 24 or 48 hours
Result: Induced cell S-phase arrest instead of causing cell apoptosis or death.

体内研究
(In Vivo)

Psoralen (oral gavage; 17.5 mg/kg; 6 weeks) reduces the number of metastatic lesions and the rate of bone metastasis by 20% compared to vehicle-treated mice. It also reduces tumor infiltration and decreases the percentage of tumor cells in metastatic lesions by ~40% compared to vehicle in mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female nude (BALB/c nu/nu) mice[2]
Dosage: 17.5 mg/kg
Administration: Oral gavage; 17.5 mg/kg; 6 weeks
Result: Inhibited metastasis of breast cancer to bone in vivo.

Clinical Trial

分子量

186.16

Formula

C11H6O3
CAS 号

66-97-7
中文名称

补骨脂素；补骨脂内酯；补骨酯素
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (537.17 mM; Need ultrasonic)

H2O : 1 mg/mL (5.37 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 5.3717 mL 26.8586 mL 53.7172 mL
5 mM 1.0743 mL 5.3717 mL 10.7434 mL
10 mM 0.5372 mL 2.6859 mL 5.3717 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (13.43 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (13.43 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (13.43 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (13.43 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (13.43 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (13.43 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Li Yin, et al. A novel psoralen derivative-MPFC enhances melanogenesis via activation of p38 MAPK and PKA signaling pathways in B16 cells. Int J Mol Med. 2018 Jun;41(6):3727-3735.

    [2]. Wu C, et al. Psoralen inhibits bone metastasis of breast cancer in mice. Fitoterapia. 2013 Dec;91:205-10.